Dynavax to Present at the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on innovative vaccines, announced that Kelly MacDonald, CFO, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. E.T. The presentation will be available via webcast on the company's investors page. Dynavax markets two key products: the HEPLISAV-B vaccine for hepatitis B and the CpG 1018 adjuvant used in COVID-19 vaccines. The company is also advancing clinical programs for shingles and influenza vaccines.

News Market Reaction – DVAX

-0.10%

-0.10% Session move

In the trading session that priced this news, DVAX declined 0.10%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Kelly MacDonald, Chief Financial Officer, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, at 2:10 p.m. E.T.

Dynavax to Present at the Cowen 43rd Annual Health Care Conference

The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018^® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-cowen-43rd-annual-health-care-conference-301760046.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax present at the Cowen 43rd Annual Health Care Conference?

Dynavax will present at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. E.T.

Who is representing Dynavax at the Cowen conference?

Kelly MacDonald, Chief Financial Officer of Dynavax, will represent the company at the Cowen conference.

Where can I watch Dynavax's presentation at the Cowen conference?

The presentation can be watched via webcast on Dynavax's investors page.

What products does Dynavax Technologies develop?

Dynavax develops the HEPLISAV-B vaccine for hepatitis B and CpG 1018 adjuvant used in COVID-19 vaccines.

What is the stock symbol for Dynavax Technologies?

The stock symbol for Dynavax Technologies is DVAX.